Risk prediction models for dementia constructed by supervised principal component analysis using miRNA expression data
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common subtype of dementia, followed by Vascular Dementia (VaD), and Dementia with Lewy Bodies (DLB). Recently, microRNAs (miRNAs) have received a lot of attention as the novel biomarkers for dementia. Here, using serum miRNA expression of 1,601 Japanese individuals, we investigated potential miRNA biomarkers and constructed risk prediction models, based on a supervised principal component analysis (PCA) logistic regression method, according to the subtype of dementia. The final risk prediction model achieved a high accuracy of 0.873 on a validation cohort in AD, when using 78 miRNAs: Accuracy = 0.836 with 86 miRNAs in VaD; Accuracy = 0.825 with 110 miRNAs in DLB. To our knowledge, this is the first report applying miRNA-based risk prediction models to a dementia prospective cohort. Our study demonstrates our models to be effective in prospective disease risk prediction, and with further improvement may contribute to practical clinical use in dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA
Shi, H., Wang, X., Lu, Z., Zhao, B. S., Ma, H., Hsu, P. J., Liu, C., & He, C. (2017) · Cell Research · doi:10.1038/cr.2017.15 · Cited by 1,815
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943
Impact of multiple pathologies on the threshold for clinically overt dementia
Kapasi, A., DeCarli, C., & Schneider, J. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1717-7 · Cited by 739
Dementia: timely diagnosis and early intervention
Robinson, L., Tang, E., & Taylor, J.-P. (2015) · BMJ · doi:10.1136/bmj.h3029 · Cited by 503
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462
Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study
Driver, J. A., Beiser, A., Au, R., Kreger, B. E., Splansky, G. L., Kurth, T., Kiel, D. P., Lu, K. P., Seshadri, S., & Wolf, P. A. (2012) · BMJ · doi:10.1136/bmj.e1442 · Cited by 425
MicroRNAs in Plasma and Cerebrospinal Fluid as Potential Markers for Alzheimer's Disease
Kiko, T., Nakagawa, K., Tsuduki, T., Furukawa, K., Arai, H., & Miyazawa, T. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-130932 · Cited by 256
Plasma microRNA biomarkers for detection of mild cognitive impairment
Sheinerman, K. S., Tsivinsky, V. G., Crawford, F., Mullan, M. J., Abdullah, L., & Umansky, S. R. (2012) · Aging · doi:10.18632/aging.100486 · Cited by 188
Cited by
Shigemizu, D., Mori, T., Akiyama, S., Higaki, S., Watanabe, H., Sakurai, T., Niida, S., & Ozaki, K. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00654-x · Cited by 103
Self-citationRyu, I. S., Kim, D. H., Ro, J.-Y., Park, B.-G., Kim, S. H., Im, J.-Y., Lee, J.-Y., Yoon, S. J., Kang, H., Iwatsubo, T., et al. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110603 · Cited by 45
Shokhirev, M. N., & Johnson, A. A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101721 · Cited by 42
“We collated publicly available microarray (Nachun et al., 2019; Narayanan et al., 2014; Sood et al., 2015; Wang et al., 2016), RNA-Seq (Magistri et al., 2015; Nativio et al., 2018; Srinivasan et al., 2020), proteomics (Johnson et al., 2020b), and miRNA array (Shigemizu et al., 2019) datasets.”
Unveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39
The role of microRNA-485 in neurodegenerative diseases
Ryu, I. S., Kim, D. H., Cho, H.-J., & Ryu, J.-H. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0039 · Cited by 25
Metadata
- Authors
- Shigemizu, D., Akiyama, S., Asanomi, Y., Boroevich, K. A., Sharma, A., Tsunoda, T., Matsukuma, K., Ichikawa, M., Sudo, H., Takizawa, S., Sakurai, T., Ozaki, K., Ochiya, T., & Niida, S.
- Venue
- Communications Biology
- Published
- 2019-02-25
- Volume
- 2
- Issue
- 1
- Pages
- 77-77
- ISSN
- 2399-3642 (ISSN-L)
- OpenAlex
- W2915790112
- Cited by
- 61
- References
- 10
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk prediction models for dementia constructed by supervised principal component analysis using miRNA expression data. https://app.cochat.ai/papers/10.1038/s42003-019-0324-7
- The paper
- Shigemizu, D., Akiyama, S., Asanomi, Y., Boroevich, K. A., Sharma, A., Tsunoda, T., Matsukuma, K., Ichikawa, M., Sudo, H., Takizawa, S., Sakurai, T., Ozaki, K., Ochiya, T., & Niida, S. (2019). Risk prediction models for dementia constructed by supervised principal component analysis using miRNA expression data. Communications Biology. https://doi.org/10.1038/s42003-019-0324-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.